Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 34
---
 of the State of Delaware. Dissenters’ Rights No dissenters’ rights are available under the General Corporation Law of the State of Delaware (the “DGCL”) or under the Certificate of Incorporation or the Second Amended and Restated Bylaws of the Company (the “Bylaws”) to any stockholder who dissents from this Proposal No. 1. Interests of Directors and Executive Officers Our directors and executive officers do not have substantial interest, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of Common Stock or any other of our securities. Vote Required; Board Recommendation The majority of the votes properly cast will be required to approve this proposal. Abstentions will have no effect on the outcome of this proposal and we do not expect any broker non -voteswith respect to such proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO COMBINE OUTSTANDING SHARES OF OUR COMMON STOCK INTO A LESSER NUMBER OF OUTSTANDING SHARES, BY A RATIO OF NOT LESS THAN ONE-FOR-             AND NOT MORE THAN ONE-FOR-            , WITH THE EXACT RATIO TO BE SET WITHIN THIS RANGE BY OUR BOARD IN ITS SOLE DISCRETION. |     | ü |

16 PROPOSAL NO. 2: NASDAQ STOCK ISSUANCE (WARRANTS) PROPOSAL Overview As described in more detail below, in February 2025, the Company issued an aggregate of 2,551,020 warrants to purchase 2,551,020shares of Common Stock in the February 2025 Registered Direct Offering (the “February 2025 Registered Direct Offering”). The Common Stock is listed on the Nasdaq Capital Market, and, as such, the Company is subject to the applicable rules of Nasdaq, including Nasdaq Listing Rules 5635(b), 5625(c) and 5635(d). Nasdaq Listing Rule 5635(b) requires the Company to obtain stockholder approval prior to certain issuances with respect to Common Stock or securities convertible into Common Stock which could result in a change of control of the issuer. Generally, Nasdaq interpretations provide that the acquisition of 20% of the shares of an issuer by one person or group of affiliated persons may be considered a change of control of such issuer. Nasdaq Listing Rule 5635(c) requires the Company to obtain